Crunching the data, the news looks relatively worse for Novo Nordisk and relatively better for rivals Eli Lilly and ... Wegovy, Mounjaro, and Zepbound lookalikes to fill a gap in supply from ...

Novo Nordisk investors may be worrying that Novo is losing market share, and may need to cut prices even further to compete with price cuts announced by Eli ... Mounjaro, and Zepbound lookalikes ...

Mounjaro®, Eli Lilly’s diabetes GLP-1 ... However, the agency may take action if an outsourcing facility continues to fill new orders after the drug is removed from shortage list, or if ...

Eli Lilly has ... and then selling the three fill-and-finish facilities in the US, Belgium, and Italy to Novo Nordisk for $11 billion. The issue was also alluded to by Lilly’s chief financial ...

Novo Nordisk has gone up another gear in its drive to boost manufacturing capacity for its fast-growing GLP-1 agonist drugs, announcing plans to build a $4.1 billion fill-and-finish facility for ...

Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, approved by CDSCO, helps with weight management and activates hormone receptors.

While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 (GLP-1) agonists in the medical world. Eli Lilly ( LLY -0.50%) has emerged ...

US-based pharmaceutical giant Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro, in India, following approval from the Central Drugs Standard Control Organisation (CDSCO).

Eli Lilly’s performance in the fourth quarter of 2024 fell short of expectations, primarily due to lower-than-anticipated sales of its flagship products Mounjaro and Zepbound. While the company ...

Eli Lilly’s performance in the fourth quarter of 2024 fell short of expectations, primarily due to lower-than-anticipated sales of its flagship products Mounjaro and Zepbound. While the company ...